Invitae Opens Early Access to Liquid Biopsy-Based Personalized Cancer Monitoring Test
Full commercial availability of the Invitae liquid biopsy-based PCM as a laboratory-developed test is expected later this year.
Read MorePosted by Melanie Hamilton-Basich | Jun 7, 2021 | Cancer |
Full commercial availability of the Invitae liquid biopsy-based PCM as a laboratory-developed test is expected later this year.
Read MorePosted by Chris Wolski | Jun 2, 2021 | Covid 19 |
Over-the-counter tests for COVID-19 approved by the U.S. Food and Drug Administration (FDA) have become common, but how good are they?
Read MorePosted by Melanie Hamilton-Basich | May 28, 2021 | Covid 19 |
FDA has granted emergency use authorization (EUA) for the Applied Biosystems TaqPath COVID-19 Pooling Kit, a highly sensitive real-time PCR multiplex test.
Read MorePosted by Melanie Hamilton-Basich | May 21, 2021 | Company News, Melanoma |
Castle Biosciences’ acquisition of CLIA-certified Myriad MyPath Laboratory from Myriad Genetics will expand its suite of genomic tests for skin cancer.
Read MorePosted by Chris Wolski | May 20, 2021 | Covid 19 |
While the tide is turning on COVID-19, clinical labs will continue to test long-haulers and the effects of the virus for years to come.
Read More